Augmentation of aortic ring contractions by angiotensin II antisense peptide

Hypertension

Volumn 31, Issue 3, 1998, Pages 854-860

  Dillon, Patrick F ^a   Root Bernstein, Robert S ^a   Holsworth, Daniel D ^b  

^a MICHIGAN STATE UNIVERSITY   (United States)

^b AMYLIN PHARMACEUTICALS INC   (United States)

Author keywords

Angiotensin II; Antisense elements; Muscle, smooth, vascular; Peptides

Indexed keywords

ANGIOTENSIN; COMPLEMENTARY DNA; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD PRESSURE REGULATION; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HYPERTENSION; MALE; MIGRAINE; MOLECULAR GENETICS; NONHUMAN; NUCLEIC ACID PROBE; PRESSOR RESPONSE; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE CONTRACTION; VASCULAR RING; VASCULAR SMOOTH MUSCLE;

EID: 0031909174     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.31.3.854     Document Type: Article

References (49)

1. Phillips MI. Antisense inhibition and adeno-associated viral vector delivery for reducing hypertension. Hypertension. 1997;29:177-187.
2. Clouston WM, Lloyd CJ, Richards R. I. Inducible antisense RNA for angiotensinogen in stably transformed hepatoma cell lines. J Mol Endocrinol. 1990;4:107-117.
3. Schinke M, Bohm M, Bricca G, Ganten D, Bader M. Permanent inhibition of angiotensinogen synthesis by antisense RNA expression. Hypertension. 1996;27:508-513.
4. Ruiz-Opazo N, Akimoto K, Herrera VLM. Identification of a novel dual angiotensin II/vasopressin receptor on the basis of molecular recognition theory. Nat Med. 1995;1:1074-1081.
5. Soffer RL, Bandyopadhyay S, Rosenberg E, Hoeprich P, Teitelbaum A, Brunck T, Colby CB, Gloff C. Unexpected binding of an octapeptide to angiotensin II receptor. Proc Natl Acad Sci U S A. 1987;84:9219-9222.
6. Elton TS, Dion LD, Bost KL, Oparil S, Blalock JE. Purification of an angiotensin II binding protein by using antibodies to a peptide encoded by angiotensin II complementary RNA. Proc Natl Acad Sci U S A. 1988;85: 2518-2522.
7. Elton TS, Oparil S, Blalock JE. The use of complementary peptides in the purification of an angiotensin II binding protein. J Hypertens Suppl. 1988; 6:S404-S407.
8. Moore GJ, Ganter RC, Franklin KJ. Angiotensin 'antipeptides': (-) messenger RNA complementary to human angiotensin II (+) messenger RNA encodes an angiotensin receptor antagonist. Biochem Biophys Res Commun. 1989;160:1387-1391.
9. Weist SA, Gesellchen PD, Zimmerman K, Steinberg MI. Binding and pharmacological properties of peptides derived from human and rat angiotensin II (AII) mRNA. Biochem Biophys Res Commun. 1990;170:462-469.
10. Budisavljevic M, Bea ML, Bensoussan M, Laubie M, Chuong PPV, Dussaule JC, Verroust PJ, Ronco PM. Antagonist effect of a receptor-mimicking peptide encoded by human angiotensin II complementary RNA. Hypertension. 1992;19:345-354.
11. Jackson EK, Prakash C, Blair IA. Studies on the peptides encoded by rat and human angiotensin II complementary RNA. Hypertension. 1993;21: 42-49.
12. Loo JA, Holsworth DD, Root-Bernstein RS. Use of electrospray ionization mass spectrometry to probe antisense peptide interactions. Biol Mass Spect. 1994;23:6-12.
13. Holsworth DD, Kiely JS, Root-Bernstein RS, Overhiser RW. Antisense-designed peptides: a comparative study focusing on possible complements to angiotensin II. Pept Res. 1994;7:185-193.
14. Root-Bernstein RS, Holsworth DD. Antisense peptides: a critical mini-review. J Theor Biol. In press.
15. Budisavljevic M, Bea ML, Bensoussan M, Laubie M, Chuong PPV, Dussaule JC, Verroust PJ, Ronco PM. Antagonist effect of a receptor mimicking peptide encoded by human angiotensin II. Hypertension. 1992; 19:345-354.
16. Mekler LB. On the specific selective interaction between ammo acid residues of polypeptide chains. Biofizika. 1969;14:581-584.
17. Biro J. Comparative analysis of specificity in protein-protein interaction. Med Hypotheses. 1981;7:969-1007.
18. Blalock JE, Smith EM. Hydropathic anti-complementarity of amino acids based on the genetic code. Biochem Biophys Res Commun. 1984;121: 203-207.
19. Bost KL, Smith EM, Blalock JE. Similarity between the corticotropin (ACTH) receptor and a peptide encoded by an RNA that is complementary to ACTH mRNA. Proc Natl Acad Sci U S A. 1985;82:1372-1375.
20. Blalock JE, Bost KL. Binding of peptides that are specified by complementary RNAs. Biochem J. 1986;234:679-683.
21. Root-Bernstein RS. Amino acid pairing. J Theor Biol. 1982;94:885-894.
22. Root-Bernstein RS. On the origin of the genetic code. J Theor Biol. 1982;94:895-904.
23. Root-Bernstein RS, Westall FC. Fibrinopeptide: a binds Gly-Pro-Arg-Pro. Proc Natl Acad Sci U S A. 1984;81:4339-4342.
24. Root-Bernstein RS, Westall FC. Bovine pineal antireproductive tripeptide binds to luteinizing hormone-releasing hormone: a model for peptide modulation by sequence specific pepride interactions? Brain Res Bull. 1986; 17:519-528.
25. Tropsha A, Kizer JS, Chaiken IM. Making sense from antisense: a review of experimental data and developing ideas on sense-antisense peptide recognition. J Mol Recognit. 1992;5:43-54.
26. Jarpe MA, Blalock JE. Complementary peptides: applications of the molecular recognition theory to peptide and protein purification and design. In: Basava C, Anantharamaiah GM, eds. Peptides: Design, Synthesis, and Biological Activity. Boston, Mass: Birkhauser; 1994:165-179.
27. Martin SF, Feisk SW, Austin RE, Eaton HL. NMR study of the possible interactions in solution of angiotensin II with a peptide encoded by angiotensin II complementary RNA. Proc Natl Acad Sci U S A. 1989;86: 9767-9769.
28. Zhou N, Moore GJ, Vogel HJ. Proton NMR studies of angiotensin II and its analogues in aqueous solution. J Protein Chem. 1991;10:333-343.
29. DeGasparo M, Whitebread S, Einsle K, Heusser C. Are the antibodies to a peptide complementary to angiotensin II useful to isolate the angiotensin II receptor? Biochem J. 1989;261:310-311.
30. Guillemette G, Boulay G, Gagnon S, Bosse R, Escher E. The peptide encoded by angiotensin II complementary RNA does not interfere with angiotensin II action. Biochem J. 1989;261:309-311.
31. Wong PC, Timmermanns PB. Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. J Pharmacol Exp Ther. 1991; 258:49-57.
32. Wong PC, Hart SD, Zaspel AM, Chiu AT, Ardecky RJ, Smith RD, Timmermans PB. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). J Pharmacol Exp Ther. 1990;255:584-592.
33. Wong PC, Bernard R, Timmermans PB. Effect of blocking angiotensin II receptor subtype on rat sympathetic nerve function. Hypertension. 1992;19; 663-667.
34. Herlihy JT, Murphy RA. Length-tension relationship of smooth muscle of the hog carotid artery. Circ Res. 1973;33:275-283.
35. Dillon PF, Murphy RA. Tonic force maintenance with reduced shortening velocity in arterial smooth muscle. Am J Physiol. 1982;242:C102-C108.
36. Dillon PF, Murphy RA. High force development and crossbridge attachment in smooth muscle from swine carotid arteries. Circ Res. 1982; 50:799-804.
37. Dickenson CJ, Lawrence JR. A slowly developing pressor response to small concentrations of angiotensin: its bearing on the pathogenesis of chronic renal hypertension. Lancet. 1063;1:1354-1356.
38. Brown AJ, Casals-Stenzel J, Goffortd S, Lever AF, Morton JJ. Comparison of fast and slow pressor effects of angiotensin II in the conscious rat. Am J Physiol. 1981;241:H381-H388.
39. Melaragno MG, Fink GD. Enhanced slow pressor effect of angiotensin II in two-kidney, one clip rats. Hypertension. 1995;25:288-293.
40. Dillon PF, Aksoy MO, Driska SP, Murphy RA. Myosin phosphorylation and the cross-bridge cycle in arterial smooth muscle. Science. 1981;211: 495-497.
41. Haeberle JR, Trybus KM, Hemric ME, Warshaw DM. The effects of smooth muscle caldesmon on actin filament motility. J Biol Chem. 1992; 267:23001-23006.
42. Lauritzen M. Cerebral blood flow in migraine and cortical spreading depression. Acta Neurol Scand Suppl. 1987;113:1-40.
43. Eberle AN, Huber M. Antisense peptides of ACTH and MSH: tools for receptor isolation? In: Mol JNM, van der Krol AR, eds. Antisense Nucleic Acids and Proteins. New York, NY: Marcel Dekker; 1991:187-208.
44. Goldstein A, Brutlag DL. Is there a relationship between DNA sequences encoding peptide ligands and their receptors? Prof Natl Acad Sci U S A. 1989;86:42-45.
45. Jurzak M, Pavo I, Fahrenholz F. Lack of interaction of vasopressin with its antisense peptides: a functional and immunological study. J Recept Res. 1993;13:881-902.
46. Masu Y, Nayakama K, Tamaki H, Harada Y, Kuno M, Nakanishi S. cDNA cloning of bovine substance-K receptor through oocyte expression system. Nature. 1987;329:836-838.
47. Najem ES, Corigliano-Murphy A, Ferretii JA. Conformational behavior of fragments of adrenocorticotropin and their antisense peptides determined by NMR spectroscopy and CD spectropolarimetry. FEBS Lett. 1989;250: 405-410.
48. Rasmussen UB, Hesch RD. On antisense peptides: the parathyroid hormone as an experimental example and a critical theoretical view. Biochem Biophys Res Commun. 1987;149:930-938.
49. Johnson HM, Torres BA. A novel arginine vasopressin-binding peptide that blocks arginine vasopressin modulation of immune functions. Biochem Biophys Res Commun. 1988;141:2420-2423.